SkinBioTherapeutics plc (AIM:SBTX)

Market Cap	46.60M
Revenue (ttm)	4.64M
Net Income (ttm)	-696.25K
Shares Out	258.91M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,342
Average Volume	1,539,970
Open	17.50
Previous Close	18.00
Day's Range	17.50 - 18.50
52-Week Range	12.00 - 27.50
Beta	0.49
RSI	54.10
Earnings Date	Jan 7, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 41
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SBTX

Financial Performance

In 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.